The Conference Board, a business research group, on Tuesday released the June update for its consumer confidence index.Economyread more
The Congressional Budget Office estimated Tuesday that the national debt will rise to 141% of the economy over the next 30 years — 11 percentage points lower than the agency...Economyread more
Investors are piling into gold, sending the precious metal to a six-year high on Monday, and analysts think the commodity has established a base to go even higher.Marketsread more
More than 150,000 former students of for-profit colleges filed a lawsuit against the U.S. Department of Education and Education Secretary Betsy DeVos on Tuesday, claiming the...Personal Financeread more
The yield on the benchmark 10-year Treasury note fell below 2% on Tuesday as investors looked for safety following the release of much weaker-than-expected confidence data.Bondsread more
Amazon announces that Amazon Prime Day will last for two days, starting July 15.Technologyread more
Investors plow into the precious metal amid the prospects for lower interest rates, a softer global economy and increased geopolitical tensions.Marketsread more
Buyers pulled away from the builders in May, even as affordability improved, thanks to lower mortgage rates.Real Estateread more
Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total value of $188.24 per Allergan share.Biotech and Pharmaceuticalsread more
CNBC's Carl Quintanilla reports from Hanoi, ahead of the Trump-Xi trade meeting, to look at Vietnam's manufacturing boom and whether it can be sustained.Economyread more
Joe Biden could face some uncomfortable questions about his record on women this week at the first Democratic presidential debates in Miami.2020 Electionsread more
For the past several months biotech stocks have fallen out of favor on Wall Street. However, last week, the group started to rally broadly.
Are biotech stocks about to rally in a sustainable manner?
For insights, Jim Cramer turned to technical analysis from Ed Ponsi, an esteemed analyst who is also the managing direction of Barchetta Capital Mangement.
"Although I like to make my ultimate decisions based on the fundamentals, I find the charts can be extremely helpful," Cramer said.
Because the iShares NASDAQ Biotechnology Index is an ETF made up of many different biotech stocks, Ponsi used it as a proxy for the sector broadly.
And looking at trendlines, Ponsi says last week, something happened that may be long-term bullish; the IBB quietly broke out above its 50-day moving average, a measure of the ETF's short-term trajectory.
It was the first time that happened since March, when it plummeted below the same key level.
In addition, Ponsi pointed out the IBB also broke out of a symmetrical triangle pattern that it had been making for weeks; breaking out of a traignel pattern is also considered bullish.
Those chart patterns, as well as others, suggest the sector could rally, broadly.
However, if you're looking for single stock opportunities, Ponsi also said the weekly chart of Celgene appeared promising with trendlines showing a bullish crossover in the Moving Average Convergence Divergence line.
Looking at fundamentals, Cramer also sees a bullish catalyst for Celgene. "It's trading at just 16 times next year's earnings estimates, which is kind of absurd for a company with a 25 percent long-term growth rate.
Read more from Mad Money with Jim Cramer
Cramer reiterates enthusiasm for GM
Cramer: Gains could be enormous
Don't give up on this tech stock, yet
All told, Ponsi sees every reason for the the IBB to rally with patterns in the charts of Celgene, Regeneron, and Isis confirming the advance . "That would mean the monster sell-off has created some terrific buying opportunities," Cramer noted. "I think Ponsi is dead right."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the "Mad Money" website? firstname.lastname@example.org